Study uncovers how OTX2 drives aggressive childhood brain cancer

FHS
July 18, 2024
11:42 pm

In a report published in Nature Cell Biology, researchers at Baylor College of Medicine, Texas Children’s Hospital, the University of Manitoba and collaborating institutions revealed an unexpected way in which the protein OTX2 drives the progression of medulloblastoma – the most common aggressive childhood brain cancer.

Opinion | ‘Alternative Facts’ Should Not Guide Reproductive Decisions

Lee is a psychiatry resident. Welcome to “The Hypocritical Oath,” my MedPage Today series where I explore ethical failures in medicine, from shortcomings in medical

June 18, 2024

J&J touts success of Vyvgart competitor in two autoimmune disease trials, including key myasthenia gravis study

Johnson & Johnson’s experimental antibody nipocalimab reduced the severity of symptoms related to two autoimmune conditions — first in a pivotal study for generalized myasthenia

February 6, 2024

EMA to discuss Pfizer’s sickle cell drug Oxbryta after patient deaths

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.